AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thiamin pyrophosphokinase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H3S4

UPID:

TPK1_HUMAN

Alternative names:

Placental protein 20; Thiamine pyrophosphokinase 1

Alternative UPACC:

Q9H3S4; A8K0T7; D3DWG0; I6L9B8; Q6NUR5; Q9H602

Background:

Thiamin pyrophosphokinase 1, also known as Placental protein 20, plays a crucial role in thiamine metabolism by catalyzing the phosphorylation of thiamine to thiamine pyrophosphate, a coenzyme essential for glucose metabolism. This protein's activity is pivotal in energy production within cells.

Therapeutic significance:

Thiamine metabolism dysfunction syndrome 5, an episodic encephalopathy type, is directly linked to mutations in the gene encoding Thiamin pyrophosphokinase 1. Understanding the role of Thiamin pyrophosphokinase 1 could open doors to potential therapeutic strategies for this metabolic disorder, offering hope for targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.